Abstract 436P
Background
With the advent of personalized medicine, recent clinical trials have placed much emphasis on the OS and PFS of cancer patients. However, several international guidelines also emphasize the need for assessing the Health Related Quality of Life (HRQoL) as part of our holistic approach in the management of cancer patients. This study evaluated the present status of the Filipino oncologists’ approach in assessing the quality of life of cancer patients.
Methods
This was a cross-sectional study that utilized a survey questionnaire. Participants included physicians in the care of the cancer patient (consultants & trainees) – medical, surgical, radiation, gynecologic oncologists, and hematologists, who were contacted via email through the database of their respective societies, and personally during scientific meetings / conferences. Descriptive and multivariate analysis were used to analyze the data.
Results
312 oncologists participated. 96% reported that HQRoL assessment was important for clinical work, however 58% perceived HRQoL to be a vague term; 69% agreed that verbal HRQoL assessments were generally enough, and 39% reported that their patients did not accept HRQoL questionnaires. Furthermore, 78% did not know which HRQoL assessment tool to use, and that the questionnaires were too extensive and too lengthy for routine use; 55% reported that they did not feel sufficiently trained to assess HRQoL. About 89.42% reported that they will be more confident if local HRQoL assessment guidelines will be present, and 92.95% agreed to the use of a unified HRQoL assessment tool for Filipino cancer patients.
Conclusions
Filipino oncologists perceived HRQoL patient assessments to be important in clinical practice. However, majority did not know which tool to use and did not feel sufficiently trained to assess HRQoL. The creation of a practice guideline that would facilitate the use of a unified HRQoL assessment tool (containing 5-15 questions) for Filipino cancer patients will be explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract